Literature DB >> 25432436

Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS).

Joanna Rupa-Matysek1, Krzysztof Lewandowski, Maria Lewandowska, Ewelina Wojtasińska, Marzena Liliana Wojtaszewska, Michał Walczak, Ksenia Bykowska, Mieczysław Komarnicki.   

Abstract

Acquired von Willebrand syndrome (AVWS) is an acquired bleeding disorder with clinical and laboratory features similar to those of the inherited form of the disease. AVWS is reported in many disorders, most frequently in myeloproliferative neoplasms and in, among others, essential thrombocythemia (ET). Interestingly, ET is associated with both the thrombotic and haemorrhagic complications, which occur in 20 % and 5-30 % of patients, respectively. The present report concerns a 38-year-old man, suffering from ET, who presented with two episodes of post-arthroscopic joint bleeding after synovectomy required for the treatment of synovial hypertrophy and chronic left knee joint synovitis. We discuss the current diagnostic approaches, as well as the risk factors predisposing to bleeding and its management, in patients with essential thrombocythemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25432436     DOI: 10.1007/s12185-014-1707-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients.

Authors:  Francesca Palandri; Nicola Polverelli; Lucia Catani; Daria Sollazzo; Emanuela Ottaviani; Sarah Parisi; Michele Baccarani; Nicola Vianelli
Journal:  Br J Haematol       Date:  2011-09-21       Impact factor: 6.998

2.  Diagnosis and treatment of acquired von Willebrand syndrome.

Authors:  Andreas Tiede
Journal:  Thromb Res       Date:  2012-12       Impact factor: 3.944

3.  Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

Authors:  G Finazzi; A Carobbio; J Thiele; F Passamonti; E Rumi; M Ruggeri; F Rodeghiero; M L Randi; I Bertozzi; A M Vannucchi; E Antonioli; H Gisslinger; V Buxhofer-Ausch; N Gangat; A Rambaldi; A Tefferi; T Barbui
Journal:  Leukemia       Date:  2011-09-16       Impact factor: 11.528

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Acquired von Willebrand syndrome: data from an international registry.

Authors:  A B Federici; J H Rand; P Bucciarelli; U Budde; P J van Genderen; H Mohri; D Meyer; F Rodeghiero; J E Sadler
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

Review 6.  The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.

Authors:  Massimo Franchini; Dino Veneri; Giuseppe Lippi
Journal:  Blood Coagul Fibrinolysis       Date:  2006-11       Impact factor: 1.276

Review 7.  How I treat the acquired von Willebrand syndrome.

Authors:  Andreas Tiede; Jacob H Rand; Ulrich Budde; Arnold Ganser; Augusto B Federici
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

8.  Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.

Authors:  Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Costanza Bogani; Alessandro Pancrazzi; Giovanni Longo; Vanessa Ponziani; Lorenzo Tozzi; Lisa Pieri; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

Review 9.  Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.

Authors:  Augusto B Federici; Ulrich Budde; Giancarlo Castaman; Jacob H Rand; Andreas Tiede
Journal:  Semin Thromb Hemost       Date:  2013-02-08       Impact factor: 4.180

10.  Early response of mouse joint tissue to noninvasive knee injury suggests treatment targets.

Authors:  P Wu; N Holguin; M J Silva; M Fu; W Liao; L J Sandell
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.